Update: Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 4, 2008, Pages 383-397

  DeNardo, Gerald L ^a   DeNardo, Sally J ^a   Balhorn, Rod ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Antibody; Non Hodgkin's lymphoma; Radioimmunotherapy; Radionuclide; Radiotherapy; Solid cancers

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RADIOISOTOPE; RITUXIMAB; SMALL MOLECULE TRANSPORT AGENT; TAXANE DERIVATIVE; TOSITUMOMAB I 131; RADIOSENSITIZING AGENT;

B CELL LYMPHOMA; CANCER RELAPSE; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; REVIEW; SALVAGE THERAPY; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; ANIMAL; ARTICLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; RADIOTHERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SALVAGE THERAPY;

EID: 51349133618     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0523-U     Document Type: Review

References (82)

1. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 2003;44:465.
2. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2004;46:128s.
3. 20+- non-Hodgkin's lymphoma. Mol Imaging Biol 2008 (in press).
4. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized, controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
6. Wiseman G, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002;99:4336.
7. 20+ B-cell lymphoma: Long-term followup of a phase I-II study. Blood 2004;103:4429.
8. 90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005;20:185.
9. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565.
10. Kashyap A, Zelenetz A, Vose J, et al. Tositumomab and iodine-131-tositumomab produce a meaningful therapeutic benefit for patients with relapsed, refractory, and transformed low-grade (LG) NHL: Summary of the long-term response population (LTRP). Proc Am Soc Clin Oncol 2003;22:576.
11. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I-131-tositumomab for chemotherapy-refractory, low-grade, or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
12. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: Update results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259.
13. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006;66:s46.
14. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441.
15. 131I-Labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 2005;23:6763.
16. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 2001;16:305.
17. Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med 2006;47:1238.
18. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys 1991;21:109.
19. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial. Cancer Res 1995;55:5921s.
20. Cagnoni PJ, Ceriani RL, Cole WC, et al. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. Cancer Biother Radiopharm 1998;13:328.
21. 90Y)-chimeric T84.66 (cT84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer. Cancer Biother Radiopharm 1998;13:314.
22. 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 1999;5:3243s.
23. 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 1997;3:1547.
24. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705.
25. Wong JYC, Somlo G, Odom-Maryon T, et al. Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res 1999;5:3224s.
26. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792.
27. DeNardo GL. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Sem Oncol 2005;32:27.
28. DeNardo GL, Tobin E, Chan K, et al. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and yttrium-90 HLA-DR antibodies. Clin Cancer Res 2005;11:7075.
29. 131I-labeled multivalent CC49 single-chain Fvs1. Clin Cancer Res 2001;7:175.
30. DeNardo SJ, Mirick GR, Kroger LA, et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73(Suppl):1023.
31. DeNardo SJ, Kroger LA, Lamborn KR, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 1997;80(Suppl):2583.
32. DeNardo SJ, Kukis DL, Kroger LA, et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Nat Acad Sci US Am 1997;94:4000.
33. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712.
34. Grunwald V, Hidalgo M. The epidermal growth-factor receptor: A new target for anticancer therapy. Curr Probl Cancer 2002;26:109.
35. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth-factor- related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 1995;19:183.
36. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689.
37. Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 2008;49:674.
38. Skvortsova I, Popper BA, Skvortsov S. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res 2005;46:241.
39. Golay J, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985;135:3795.
40. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336.
41. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270.
42. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934.
43. Gopal AK, Rajendran JG, Petersdorf SH. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158.
44. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate-and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000;1:46.
45. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: A multivariable cohort analysis. Blood 2003;102:2351.
46. Press OW, Unger JM, Braziel RM, et al. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131-tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. Blood 2003;102:1606.
47. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992;33:1648.
48. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Nat Cancer Inst 1990;82:763.
49. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations in fractionated radioimmunotherapy. Cancer 2002;94:1332.
50. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 1997;38:1180.
51. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239.
52. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
53. Boerman OC, van Schaijk FG, Oyen WJG, et al. Pretargeted radioimmunotherapy of cancer: A progress step by step. J Nucl Med 2003;44:400.
54. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110.
55. Goldenberg DM, Chatal JF, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007;2:19.
56. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340.
57. Pagel JM, Lin Y, Hedin N, et al. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 2006;108:328.
58. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535.
59. Weiden PL, Breitz HB, Press OW, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 2000;15:15.
60. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 2008;111:2261.
61. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109s.
62. Forero A, Weiden PL, Vose JM, et al. A phase I trial of a novel anti-CD20 fusion protein in pretargeting radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood 2004;104:227.
63. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Nat Acad Sci US Am 2000;97:1802.
64. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158.
65. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. PNAS 2006;103:6841.
66. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823.
67. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Meth Mol Biol 2004;248:209.
68. Krenning EP, Teunissen JJ, Valkema R. Molecular radiotherapy with somatostatin analogs for (neuro) endocrine tumors. J Endocrinal Invest 2005;28:146.
69. Breeman WA, de Jong M, de Blois E. Radiolabeling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478.
70. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67S.
71. 3]octreotide in patients with advanded gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147.
72. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S.
73. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213.
74. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: Current status. J Clin Oncol 2004;22:3593.
75. Missailidis S, Perkins A. Aptamers as novel radiopharmaceuticals: Their applications and future prospects in diagnosis and therapy. Cancer Biother Radiopharm 2007;22:453.
76. Orlova A, Feldwisch J, Abrahmsen L, et al. Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007;22:573.
77. Balhorn R, Hok S, Burke P, et al. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res 2007;13:5621s.
78. West J, Perkins J, Hok S, et al. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm 2006;21:645.
79. DeNardo GL, Hok S, Natarajan A, et al. Characteristics of dimeric (bis) bidentate selective high-affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol 2007;31:729.
80. Hok S, Natarajan A, Balhorn R, et al. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconj Chem 2007;18:912.
81. DeNardo GL, Natarajan A, Hok S, et al. Novel nanomolecular HLA-DR10 antibody mimics provide a potent system for molecular therapy and imaging. J Nucl Med 2008;49:319P.
82. Costantini DL, Chan C, Cai Z, et al. 111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357.